

**THE FOLLOWING ARE THE ENGLISH TRANSLATION
OF ANNEXES TO THE INTERNATIONAL PRELIMINARY
EXAMINATION REPORT (ARTICLE 34):**

Amended Specification (Pages 60-63)

Claims

1. (After Amendment) A therapeutic agent for
Parkinson's disease, cerebral infarction, head injuries,
5 cerebral hemorrhage, spinal injuries, which comprises a PPAR δ
agonist as an active ingredient.

2. (After Amendment) A therapeutic method for
Parkinson's disease, cerebral infarction, head injuries,
10 cerebral hemorrhage, spinal injuries, which comprises
administering a pharmaceutical agent comprising a PPAR δ
agonist as an active ingredient.

3. A therapeutic agent for cerebral infarction,
15 which comprises a PPAR δ agonist as an active ingredient.

4. A therapeutic agent for Parkinson's disease,
which comprises a PPAR δ agonist as an active ingredient.

20 5. A therapeutic method for cerebral infarction,
which comprises administering a pharmaceutical agent
comprising a PPAR δ agonist as an active ingredient.

6. A therapeutic method for Parkinson's disease,
25 which comprises administering a pharmaceutical agent
comprising a PPAR δ agonist as an active ingredient.

7. The therapeutic agent according to claim 1, 3
or 4, wherein the PPAR δ agonist is a PPAR δ agonist
specifically re-selected using the activity of suppressing
5 cellular death as the marker.

8. The therapeutic method according to claim 2, 5
or 6, wherein the PPAR δ agonist is a PPAR δ agonist
specifically re-selected using the activity of suppressing
10 cellular death as the marker.

9. The therapeutic agent according to claim 1, 3
or 4, wherein the PPAR δ agonist is L-165041 or GW501516.

15 10. The therapeutic method according to claim 2, 5
or 6, wherein the PPAR δ agonist is L-165041 or GW501516.

11. (After Amendment) Use of a PPAR δ agonist for
the manufacture of a therapeutic agent for Parkinson's
20 disease, cerebral infarction, head injuries, cerebral
hemorrhage, spinal injuries.

12. Use of a PPAR δ agonist for the manufacture of a
therapeutic agent for cerebral infarction.

13. Use of a PPAR δ agonist for the manufacture of a therapeutic agent for Parkinson's disease.

14. The use according to any of claims 11 through
5 13, wherein the PPAR δ agonist is a PPAR δ agonist specifically re-selected using the activity of suppressing cellular death as the marker.

15. The use according to any of claims 11 through
10 13, wherein the PPAR δ agonist is a PPAR δ agonist specifically re-selected using the activity of suppressing cellular death as the marker.

16. An agent of suppressing the death of central
15 nerve cell, which comprises a PPAR δ agonist as an active ingredient.

17. The agent of suppressing the death of central
nerve cell according to claim 16, wherein the PPAR δ agonist
20 is L-165041 or GWW501516.

18. (addition) An agent of suppressing the death of
central nerve cell in cerebral hemorrhage, which comprises a
PPAR δ agonist as an active ingredient.

25

19. (addition) An agent of suppressing the death of central nerve cell in acute stage of cerebral infarction, which comprises a PPAR δ agonist as an active ingredient.